DE69633396D1 - Activin stimulator enthaltende pharmazeutische zusammensetzung - Google Patents

Activin stimulator enthaltende pharmazeutische zusammensetzung

Info

Publication number
DE69633396D1
DE69633396D1 DE69633396T DE69633396T DE69633396D1 DE 69633396 D1 DE69633396 D1 DE 69633396D1 DE 69633396 T DE69633396 T DE 69633396T DE 69633396 T DE69633396 T DE 69633396T DE 69633396 D1 DE69633396 D1 DE 69633396D1
Authority
DE
Germany
Prior art keywords
stimulator
pharmaceutical composition
composition containing
containing activin
activin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69633396T
Other languages
English (en)
Other versions
DE69633396T2 (de
Inventor
William Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of DE69633396D1 publication Critical patent/DE69633396D1/de
Application granted granted Critical
Publication of DE69633396T2 publication Critical patent/DE69633396T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Adornments (AREA)
  • Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69633396T 1995-10-21 1996-10-17 Activin stimulator enthaltende pharmazeutische zusammensetzung Expired - Lifetime DE69633396T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9521608 1995-10-21
GB9521608A GB2306481A (en) 1995-10-21 1995-10-21 Pharmaceutical comprising a stimulator of activin and/or inhibin
PCT/GB1996/002559 WO1997015321A1 (en) 1995-10-21 1996-10-17 Pharmaceutical composition containing an activin or inhibin stimulator

Publications (2)

Publication Number Publication Date
DE69633396D1 true DE69633396D1 (de) 2004-10-21
DE69633396T2 DE69633396T2 (de) 2005-09-22

Family

ID=10782702

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633396T Expired - Lifetime DE69633396T2 (de) 1995-10-21 1996-10-17 Activin stimulator enthaltende pharmazeutische zusammensetzung

Country Status (13)

Country Link
US (1) US7713933B2 (de)
EP (1) EP0855916B1 (de)
JP (1) JP4102437B2 (de)
AT (1) ATE275966T1 (de)
AU (1) AU715255B2 (de)
CA (1) CA2235412C (de)
DE (1) DE69633396T2 (de)
DK (1) DK0855916T3 (de)
ES (1) ES2227610T3 (de)
GB (1) GB2306481A (de)
PT (1) PT855916E (de)
WO (1) WO1997015321A1 (de)
ZA (1) ZA968785B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
WO2001043763A1 (en) * 1999-12-15 2001-06-21 Research Development Foundation Betaglycan as an inhibin receptor and uses thereof
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
AU2009262970A1 (en) 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
KR20210119546A (ko) 2014-06-04 2021-10-05 악셀레론 파마 인코포레이티드 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
AU2016238254B2 (en) 2015-03-26 2022-05-05 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
WO2017088027A1 (en) * 2015-11-26 2017-06-01 Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research Inhibin analogs
CN115404199B (zh) * 2022-11-01 2023-03-21 广州优特佳生物科技发展有限公司 活化素b在促进透明质酸合成中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011862A1 (en) * 1988-05-31 1989-12-14 Biotechnology Australia Pty. Ltd. Actions of hormones
US5071834A (en) * 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
US4997815A (en) * 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
JPH0651638B2 (ja) * 1989-02-13 1994-07-06 新技術事業団 角膜上皮創傷治療用点眼剤
US5102868A (en) * 1990-01-08 1992-04-07 Genentech, Inc. Method for inhibiting follicular maturation
EP0515494A1 (de) * 1990-02-15 1992-12-02 Chiron Corporation Verwendung von cytokinaktivitätsinhibitor
WO1992004913A1 (en) * 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5216004A (en) * 1990-09-13 1993-06-01 Children's Hospital Medical Center Of North California Method for preventing malaria
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
AU660019B2 (en) 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
IL99867A0 (en) 1991-10-27 1992-08-18 Yissum Res Dev Co Pharmaceutical compositions containing activin a
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US5428011A (en) * 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US5888720A (en) 1992-10-27 1999-03-30 Yissum Research And Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs
JPH07149659A (ja) * 1993-09-28 1995-06-13 Ajinomoto Co Inc 骨損傷治療剤
ES2140670T3 (es) * 1994-03-29 2000-03-01 Univ Manchester Cicatrizacion de heridas.
AU716811B2 (en) 1994-11-14 2000-03-09 Neurospheres Holdings Ltd Regulation of neural stem cell proliferation

Also Published As

Publication number Publication date
ES2227610T3 (es) 2005-04-01
WO1997015321A1 (en) 1997-05-01
DK0855916T3 (da) 2004-10-18
GB2306481A (en) 1997-05-07
PT855916E (pt) 2004-11-30
JP4102437B2 (ja) 2008-06-18
ATE275966T1 (de) 2004-10-15
ZA968785B (en) 1998-04-20
AU715255B2 (en) 2000-01-20
US20040052795A1 (en) 2004-03-18
JPH11514373A (ja) 1999-12-07
AU7313896A (en) 1997-05-15
DE69633396T2 (de) 2005-09-22
CA2235412A1 (en) 1997-05-01
EP0855916B1 (de) 2004-09-15
US7713933B2 (en) 2010-05-11
EP0855916A1 (de) 1998-08-05
CA2235412C (en) 2010-01-19
GB9521608D0 (en) 1996-01-03

Similar Documents

Publication Publication Date Title
ZA966744B (en) Pharmaceutical composition.
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
ES2194308T3 (es) Utilizacion de sustancias con una actividad de oxitocina en la preparacion de medicamentos para la curacion de heridas.
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
DE69633396D1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
DE69626987D1 (de) Pharmaceutische komposition
AU7999787A (en) Active compounds for use in the treatment of tumors
GB9516073D0 (en) Pharmaceutical composition
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
GB9723824D0 (en) Cytostatic agents
NO991047D0 (no) Transdermal terapeutisk tilnµrming involverende en kombinasjon av aktive substanser inneholdende °striol
YU40098A (sh) Upotreba olanzapina za dobijanje leka
GEP20002177B (en) Ointment “Levaskani” for Treatment of Wounds and Burns
UA8280A (uk) Спосіб лікування псоріазу
HUP9801869A2 (hu) Készítmény az L-karnitinszint megnövelésére emberben
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь

Legal Events

Date Code Title Description
8364 No opposition during term of opposition